Selective Intratumoral Amplification of an Antiangiogenic Vector by an Oncolytic Virus Produces Enhanced Antivascular and Anti-tumor Efficacy
Open Access
- 31 May 2006
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (5), 938-946
- https://doi.org/10.1016/j.ymthe.2005.12.010
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Adeno-associated virus vectors: potential applications for cancer gene therapyCancer Gene Therapy, 2005
- VEGF-Targeted Therapy: Therapeutic Potential and Recent AdvancesThe Oncologist, 2005
- Tumour vascular targetingNature Reviews Cancer, 2005
- Versatility of gene therapy vectors through virusesExpert Opinion on Biological Therapy, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Combination Therapy with Conditionally Replicating Adenovirus and Replication Defective AdenovirusCancer Research, 2004
- Ablating CAR and Integrin Binding in Adenovirus Vectors Reduces Nontarget Organ Transduction and Permits Sustained Bloodstream Persistence Following Intraperitoneal AdministrationMolecular Therapy, 2004
- Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer TherapyCancer Research, 2004
- Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genesCancer Gene Therapy, 2002
- Gene delivery from replication-selective viruses: arming guided missiles in the war against cancerJournal of Clinical Investigation, 2000